Addex Therapeutics (ADXN) announced that following the previously announced termination of development of ADX71149 in epilepsy, its partner Janssen Pharmaceuticals (JNJ) has returned all development and commercialization rights to ADX71149 and the partnership between the two companies has been terminated.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.